# Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

> **NCT00894387** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1639 (actual)

## Conditions studied

- Acute Decompensated Heart Failure
- Congestive Heart Failure

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00894387
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 1639 (ACTUAL)
- **Last updated:** 2013-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00894387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00894387, "Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00894387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*